Skip to content
Research Article Open access CC BY 4.0

Intravenous Bisphosphonate Therapy in the Adult Patient with Osteogenesis Imperfecta: A Literature Review and Case Report

Haydn James Taylor, Stephanie Cox, Jennifer Georgina Martins, Michael O'Halloran

International Journal of Medical and Pharmaceutical Case Reports · pp. 1–5 · Published 23 Aug 2015

10.9734/IJMPCR/2015/19425

Abstract

Osteogenesis Imperfecta (OI) defines a group of genetically varied connective tissue disorders where intravenous bisphosphonate (BP) therapy is common to manage the associated bone fragility. Due to this bone fragility, there is potential for these patients to be regarded as a high-risk group for BP-related osteonecrosis of the jaw (BRONJ). First documentation of BRONJ was in 2003; however few reports discuss the risk of BRONJ relative to BP therapy in patients with OI. Of these reported cases of BRONJ, all have been recorded in patients sixty years and over.  As yet, no literature is available to show if OI in adults increases the risk of BRONJ. In this case, a 59-year-old male, receiving intravenous BP therapy for OI, underwent multiple dental extractions under local anesthesia. At subsequent review appointments, no clinical signs of BRONJ were detected.

Osteogenesis imperfect bisphosphonates BRONJ oral surgery.

Cited by 0

No indexed citations yet.

Article metrics

Real usage data collected on this platform.

0

Page views

0

PDF downloads

0

Outbound clicks

0

Citations

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

No views recorded yet.

Traffic sources

Referring site, by host.

No traffic recorded yet.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.